CAMP Camp4 Therapeutics Corp Insider Trading

10% Owner 5AM Partners VI buys 2.94M shares of CAMP at $1.53; stock now -77.4% from 52-week high amid unprofitable operations and cluster buy pattern.

5AM Partners VI purchased 2,941,176 shares at $1.53 on 2025-09-11, representing a new 2.94M share position in Camp4 Therapeutics. The current price of $2.65 reflects a -77.4% decline from the 52-week high of $11.74, though the stock has recovered +58.7% over the past 30 days and +90.6% over 90 days. Historically, this insider's prior buy at CAMP on 2024-10-15 posted a 90-day return of -64.1%, and across all tickers, the insider's 2 prior buys averaged a 90-day return of -31.3%. The transaction occurs alongside a cluster of 6 other insiders who bought within the past 14 days. Camp4 remains unprofitable with a net income of $-12,587,000.00 over its most recent full fiscal year, though the company posted +86.3% annual revenue growth. The $53.4M market cap and severe valuation compression create a high-risk recovery narrative that the cluster activity does not validate based on the insider's prior track record at this same ticker.

CFO Gold Kelly buys 6.1K shares at $1.65; 6 other insiders also bought within 14 days as stock trades 76.3% below 52-week high.

Gold Kelly purchased 6,060 shares at $1.65 on 2025-09-11, increasing his holdings by 9.8% to 67.9K shares total. The transaction coincides with a broader insider acquisition pattern: 6 other insiders also bought within the past 14 days, forming a cluster buy signal at a moment when CAMP trades $2.78—down 76.3% from its 52-week high of $11.74 yet up 101.4% over the prior 30 days. The company remains unprofitable with a $-12.6M net loss over its most recent full fiscal year, though it posted strong 86.3% annual revenue growth to $1.5M (latest quarter). The convergence of multiple insider purchases during a period of elevated volatility and significant valuation compression, combined with the company's pre-profitability status, warrants investor attention to the underlying catalysts driving coordinated insider accumulation.

10% owner Polaris Management VII buys 1,307,189 shares ($2.0M) at $1.53 on CAMP; stock +101.4% in 30 days but -76.3% from 52-week high.

Polaris Management Co. VII, L.L.C., a 10% owner, completed 2 separate purchases totaling 1,307,189 shares for $1,999,999.17 at a blended average price of $1.53 on 2025-09-11, bringing post-transaction holdings to 197,661 shares. The timing of this substantial $2.0M investment coincides with a significant rally—the stock has risen +101.4% over 30 days and +80.5% over 90 days—though it remains -76.3% below its 52-week high of $11.74. The insider's prior purchase at this same ticker on 2024-10-15 exhibited weak timing outcomes (30d -12.6%, 90d -64.1%), and across all of Polaris's open-market history, the firm shows a 0.00% 90-day win rate with an average 90d return of -64.1%. A cluster pattern is present: 6 other insiders also bought CAMP within the past 14 days. The company generated $1,497,000.00 in latest-quarter revenue against a $-12,587,000.00 net loss and remains unprofitable on a full-year basis, though annual revenue growth reached +86.3%.

Director Young Richard A bought 15.2K shares of CAMP at $1.65; 6 other insiders also bought within 14 days, cluster pattern amid 170.0K post-transaction holdings.

Director Young Richard A purchased 15,151 shares at $1.65 on 2025-09-11, increasing his holdings by 9.8% to 170,010 shares total. This transaction is part of a cluster pattern: 6 other insiders also bought within the past 14 days, indicating coordinated insider purchasing activity. The company is unprofitable (net income of $-12,587,000.00 over the most recent full fiscal year) but shows strong revenue growth of 86.3% year-over-year, with latest quarter revenue at $1,497,000.00. The stock has rebounded significantly in the short term (+101.4% over 30 days and +80.5% over 90 days) but remains -76.3% below its 52-week high of $11.74, trading at $2.78 currently. The convergence of multi-insider buying, strong revenue growth trajectory, and depressed valuation relative to recent range deserves investor attention to understand the insiders' rationale.

Camp4 Director Nashat Amir bought 1,307,189 shares for $1,999,999.17 at $1.53 on 2025-09-11; 6-insider cluster buy

Nashat Amir, Camp4 Therapeutics Director, executed 2 separate purchases totaling 1,307,189 shares for $1,999,999.17 at $1.53, resulting in a post-transaction holding of 197,661 shares. The stock trades at $2.78 currently, down 76.3% from its 52-week high of $11.74, though up 101.4% over the past 30 days. Amir's prior same-ticker buy on 2024-10-15 saw negative returns at both 30-day (-12.6%) and 90-day (-64.1%) horizons, with zero wins across his cross-ticker open-market purchase history. The filing occurs within a broader cluster pattern: 6 other insiders also bought within the past 14 days, suggesting coordinated or mutually reinforcing acquisition timing. Against this backdrop, Camp4 reports severe operating losses ($-12,587,000.00 net income in the latest quarter) despite strong annual revenue growth of 86.3%, leaving the unprofitable biotech's strategic direction and near-term cash position as critical factors for monitoring.

CMO Maricich Yuri buys 6,060 shares at $1.65; 6 insiders bought in past 14 days as stock surges 101.4% in 30 days.

Maricich Yuri, Chief Medical Officer, purchased 6,060 shares at $1.65 on 2025-09-11, establishing a new position of 6,060 shares with a transaction value of $9,999.00. This buy is part of a cluster pattern: 6 other insiders also purchased shares within the past 14 days, suggesting coordinated conviction at a specific price level. The timing is notable given recent price action—the stock has risen 101.4% in the past 30 days and 80.5% in the past 90 days, yet is still 76.3% below its 52-week high of $11.74, indicating recovery from a significantly depressed level. The company remains unprofitable (net income $-12.6M in the latest fiscal year), though revenue growth has been strong at 86.3% annually. The cluster buy pattern coinciding with sharp recent gains suggests insiders perceive the recovery as substantive rather than speculative, but investors should note the company's ongoing losses and whether this climb reflects durable operational progress or temporary momentum.

Camp4 CEO Josh Mandel-Brehm bought 6,060 shares at $1.65 on 2025-09-11; 6 other insiders also bought within 14 days

Chief Executive Officer Josh Mandel-Brehm purchased 6,060 shares at $1.65 for $10.0K, increasing holdings from 272,357 to 278,417 shares. This open-market buy occurs within a cluster pattern: 6 other insiders also purchased shares within the past 14 days. The stock has recovered 101.4% over the past 30 days and 80.5% over 90 days, though it remains 76.3% below its 52-week high of $11.74. Camp4 is unprofitable (net income of $-12.6M in its latest full fiscal year) despite strong annual revenue growth of 86.3%, with latest quarterly revenue at $1.5M. The coincident buying by multiple insiders at a depressed valuation relative to 52-week highs, coupled with the company's explosive revenue trajectory, suggests insiders may view the current price as attractive amid a recovery phase.

10% owner Enavate Sciences buys 1,363,636 CAMP shares at $11.00 ($15.0M), holdings rise to 3,785,802 shares; 6 insiders also bought in past 14 days

Enavate Sciences GP, LLC, a 10% owner, purchased 1,363,636 shares at $11.00 on 2024-10-15, increasing holdings from 2,422,166 to 3,785,802 shares. This $15.0M investment represents a 56.3% increase in the filer's shareholding. The transaction occurred within a 14-day window in which 6 other insiders also executed purchases—a cluster buy pattern that suggests coordinated insider interest. At the $10.86 current price, the stock is -0.6% from its 52-week high of $10.92, having surged +2615.0% over the past 30 and 90 days, indicating recent material price appreciation. The timing of this large accumulation alongside broad insider buying interest merits investor scrutiny of what event or catalyst may have triggered the coordinated activity.

Northpond Ventures II GP buys 763.6K CAMP shares at $11.00 ($8.4M); cluster buy with 6 other insiders in 14 days

Northpond Ventures II GP, a 10% owner, purchased 763,636 shares at $11.00 on 2024-10-15 for $8,399,996.00, establishing an initial shareholding position. This transaction is part of a cluster pattern: 6 other insiders also bought within the past 14 days, indicating coordinated or simultaneously motivated acquisition activity. The current stock price of $10.86 is -0.6% from the 52-week high of $10.92, suggesting the purchase occurred near recent peak valuations. The 30-day and 90-day price changes of +2615.0% underscore the stock's extreme volatility and recent dramatic appreciation, which provides material context for evaluating the timing and conviction behind this significant $8.4M acquisition by a major shareholder.

AH Equity Partners Bio I (10% owner) bought 727,272 shares for $7,999,992.00 at $11.00; cluster buy pattern with 6 other insiders in 14 days.

AH Equity Partners Bio I executed 2 separate purchases totaling 727,272 shares for $7,999,992.00 at a blended average price of $11.00 on 2024-10-15. This is a significant capital commitment from a substantial 10% shareholder, and the transaction occurs within a broader cluster pattern: 6 other insiders also bought within the past 14 days. The current price of $10.86 is -0.6% from the 52-week high, and the stock has appreciated +2615.0% over both the 30-day and 90-day periods. The concentration of buying activity across multiple insiders during a period of steep appreciation warrants attention, though the form filing is subject to a derivative-conversion flag indicating the shareholder's full position may extend beyond the Table I holdings shown.